Keld Søndergaard leaves Xintela's Board of DirectorsXintela AB (publ) announces that Keld Søndergaard has resigned from the company's Board of Directors, citing personal reasons. Xintela's larger shareholders, acting as an informal nomination committee, will consider potential replacement candidates to propose to the next Annual General Meeting. Keld Søndergaard was elected as a new member of the Board at the Annual General Meeting on the 18th of May 2017. The Board regrets the loss of Keld as a member, but feels certain a suitable replacement will be found.
Shareholders who have suggestions for appropriate candidates may contact the Chairman, Greg Batcheller, via the CEO Evy Lundgren-Åkerlund.
The Xintela Board wishes Keld Søndergaard all the best in his future endeavors. Lund, Sweden, 17th of October 2017 Xintela AB (publ) Evy Lundgren-Åkerlund, vd
Tel: 070-329 18 71
E-post: [email protected]
Medicon Village
223 81 Lund
www.xintela.se
For investor relations and media questions, please contact:
Mårten Svanberg, Laika Consulting
Tel: 070-362 70 05
E-post: [email protected]
www.laika.se
This information is such information that Xintela AB (publ) is obligated to publish in compliance with the EU market abuse regulation. The information was provided, through the above contact, for publication on the 17th of October 2017, at 09.00 CET.
The following documents can be retrieved from beQuoted
Xintela Pressrelease 2017-10-17 English.pdf About Xintela
Xintela develops medical products for regenerative medicine and cancer based on its proprietary marker technology, XINMARK®. Xintela uses the technology to select and assure the quality of mesenchymal stem cells for the treatment of cartilage damage and osteoarthritis. In a study on horses, the company has shown that stem cells are safe to use and that they have a positive effect on the articular cartilage and the underlying bone after an injury. XINMARK® is also used for the development of an antibody- based treatment (Antibody Drug Conjugate, ADC) against glioblastoma, the most common and aggressive form of brain tumors in adults. Positive preclinical results from cell studies and animal model have shown that the antibody has a killing effect on glioblastoma cells and thus has confirmed the concept. Xintela is listed on Nasdaq First North Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North is Erik Penser Bank AB, +46 8-463 80 00.
If you want to open the text in your webbrowser
click here
______________________________________________________
This information was sent by beQuoted
If you want more information, please go to www.beQuoted.com
To change your subscription, please inform [email protected] beQuoted Press är en service till Dig som är intresserad av finansiell information. Med beQuoted Press underlättas företagens finansiella kommunikation till Dig och till nyhetsbyråer, aktieägare, placeringsrådgivare och andra intressenter på aktiemarknaden.
Vi hoppas att Du uppskattar denna service.
| 